Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 85126244 | 8512624 | 4 | F | 2008 | 20160725 | 20120413 | 20160802 | EXP | US-ASTRAZENECA-2011SE77190 | ASTRAZENECA | 62.00 | YR | F | Y | 0.00000 | 20160802 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 85126244 | 8512624 | 1 | PS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | 233760 | MG | 21957 | 40 | MG | QD | ||||||
| 85126244 | 8512624 | 2 | SS | TOPROL XL | METOPROLOL SUCCINATE | 1 | Oral | 0 | 50 | MG | MODIFIED-RELEASE TABLET | QD | |||||||
| 85126244 | 8512624 | 3 | SS | CRESTOR | ROSUVASTATIN CALCIUM | 1 | Oral | 0 | 10 | MG | TABLET | QD | |||||||
| 85126244 | 8512624 | 4 | SS | NIASPAN | NIACIN | 1 | Unknown | U | 0 | ||||||||||
| 85126244 | 8512624 | 5 | C | LEXAPRO | ESCITALOPRAM OXALATE | 1 | 0 | ||||||||||||
| 85126244 | 8512624 | 6 | C | NEURONTIN | GABAPENTIN | 1 | 0 | ||||||||||||
| 85126244 | 8512624 | 7 | C | WELLBUTRIN | BUPROPION HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 85126244 | 8512624 | 8 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Oral | 0 | 500 | MG | BID | ||||||||
| 85126244 | 8512624 | 9 | C | LEVOTHYROXINE. | LEVOTHYROXINE | 1 | Oral | 0 | 100 | UG | QD | ||||||||
| 85126244 | 8512624 | 10 | C | VITAMIN D2 | ERGOCALCIFEROL | 1 | 0 | /wk | |||||||||||
| 85126244 | 8512624 | 11 | C | VICTOZA | LIRAGLUTIDE | 1 | Subcutaneous | 6 UNITS ,DAILY. | 0 | ||||||||||
| 85126244 | 8512624 | 12 | C | VICTOZA | LIRAGLUTIDE | 1 | Subcutaneous | 12 UNITS ,DAILY. | 0 | ||||||||||
| 85126244 | 8512624 | 13 | C | VICTOZA | LIRAGLUTIDE | 1 | Subcutaneous | 18 UNITS ,DAILY. | 0 | ||||||||||
| 85126244 | 8512624 | 14 | C | LEVEMIR | INSULIN DETEMIR | 1 | Subcutaneous | 20 U,EVENING | 0 | ||||||||||
| 85126244 | 8512624 | 15 | C | NOVOLOG | INSULIN ASPART | 1 | 10 U AT LUNCH AND 10 U AT BEDTIME. | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 85126244 | 8512624 | 1 | Gastrooesophageal reflux disease |
| 85126244 | 8512624 | 2 | Heart rate decreased |
| 85126244 | 8512624 | 3 | Blood cholesterol abnormal |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 85126244 | 8512624 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 85126244 | 8512624 | Blood cholesterol increased | |
| 85126244 | 8512624 | Blood glucose increased | |
| 85126244 | 8512624 | Depression | |
| 85126244 | 8512624 | Diabetes mellitus | |
| 85126244 | 8512624 | Drug dose omission | |
| 85126244 | 8512624 | Endocrine disorder | |
| 85126244 | 8512624 | Hypothyroidism | |
| 85126244 | 8512624 | Intraductal proliferative breast lesion | |
| 85126244 | 8512624 | Osteoporosis | |
| 85126244 | 8512624 | Tachycardia | |
| 85126244 | 8512624 | Weight increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 85126244 | 8512624 | 1 | 2000 | 0 |